Allogene Therapeutics



Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized ...

Alison Moore
Chief Technical Officer
Barbra Sasu
Chief Scientific Officer
Christine Cassiano
Chief Communications Officer
Eric T. Schmidt
Chief Financial Officer
Rafael G. Amado
EVP of Research & Development & Chief Medical Officer
Veer Bhavnagri
General Counsel

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.